SHP Share Price

Open 4531.50 Change Price %
High 4531.50 1 Day -204.00 -4.47
Low 4324.50 1 Week -320.50 -6.85
Close 4357.00 1 Month -210.50 -4.61
Volume 3117976 1 Year -158.00 -3.50
52 Week High 5377.00
52 Week Low 2707.19
SHP Important Levels
Resistance 2 4548.89
Resistance 1 4469.82
Pivot 4404.33
Support 1 4244.19
Support 2 4165.11
LON UK Most Active Stocks
LGO 0.14 27.27%
LGO 0.14 27.27%
LGO 0.14 27.27%
LLOY 61.76 3.83%
CWC 74.60 0.27%
CWC 74.60 0.27%
CWC 74.60 0.27%
INC 0.04 -20.00%
OTC 0.02 -33.33%
OTC 0.02 -33.33%
More..
LON UK Top Gainers Stocks
AKT 28.50 5177.78%
HHR 58.00 900.00%
GPX 11.65 127.54%
GPX 11.65 127.54%
BAF 99.80 116.96%
BAF 99.80 116.96%
BAF 99.80 116.96%
MES 0.28 75.00%
MES 0.28 75.00%
MES 0.28 75.00%
More..
LON UK Top Losers Stocks
ENDV 0.02 -99.85%
KEA 0.10 -91.30%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
DCP 0.50 -75.61%
ASBE 25.00 -58.33%
PCI 3.50 -53.27%
PCI 3.50 -53.27%
OTC 0.02 -33.33%
More..

Shire PLC (LON: SHP)

SHP Technical Analysis 4
As on 7th Dec 2016 SHP Share Price closed @ 4357.00 and we RECOMMEND Sell for LONG-TERM with Stoploss of 4465.39 & Strong Sell for SHORT-TERM with Stoploss of 4877.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
SHP Target for December
1st Target up-side 5154.92
2nd Target up-side 5489.55
3rd Target up-side 5824.18
1st Target down-side 4200.08
2nd Target down-side 3865.45
3rd Target down-side 3530.82
SHP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.shire.com
SHP Address
SHP
5 Riverwalk
Citywest Business Campus
Dublin, 24
Ireland
Phone: 353 1 429 7700
Interactive Technical Analysis Chart Shire PLC ( SHP LON UK )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Shire PLC
SHP Business Profile
Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.